Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma.

Kotoulas, Serafeim Chrysovalantis; Tsiouprou, Ioanna; Fouka, Eva; Pataka, Athanasia; Papakosta, Despoina; Porpodis, Konstantinos

Kotoulas, Serafeim Chrysovalantis; Tsiouprou, Ioanna; Fouka, Eva; Pataka, Athanasia; Papakosta, Despoina; Porpodis, Konstantinos.

Afiliação

Kotoulas SC; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. Papanikolaou'' General Hospital, Exohi, 57010 Thessaloniki, Greece.
Tsiouprou I; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. Papanikolaou'' General Hospital, Exohi, 57010 Thessaloniki, Greece.
Fouka E; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. Papanikolaou'' General Hospital, Exohi, 57010 Thessaloniki, Greece.
Pataka A; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. Papanikolaou'' General Hospital, Exohi, 57010 Thessaloniki, Greece.
Papakosta D; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. Papanikolaou'' General Hospital, Exohi, 57010 Thessaloniki, Greece.
Porpodis K; Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. Papanikolaou'' General Hospital, Exohi, 57010 Thessaloniki, Greece.

J Pers Med ; 12(2)2022 Jan 26.

Article em En | MEDLINE | ID: mdl-35207654

Palavras-chave

IgE; omalizumab; severe allergic asthma

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Pers Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Grécia